Antiangiogenic therapy for primary and metastatic brain tumors

Area of Science:

• Neuro-oncology
• Vascular Biology
• Cancer Therapeutics

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for brain tumor growth and progression.
• Antiangiogenic therapy aims to inhibit this process, starving tumors of nutrients and oxygen.
• Both primary and metastatic brain tumors rely on angiogenesis, though metastases are less studied.

Purpose of the Study:

• To provide a theoretical foundation for antiangiogenic therapy in brain tumors.
• To review preclinical experimental therapies for brain tumors.
• To summarize clinical trial data and ongoing trials for brain tumors.

Main Methods:

• Review of the biology of angiogenesis in the context of brain tumors.
• Survey of preclinical antiangiogenic therapies applied to brain tumors.
• Analysis of published and ongoing clinical trial data.

Main Results:

• The review details the biological basis of antiangiogenic therapy for brain tumors.
• Experimental therapies are being explored preclinically.
• Clinical trial data, though limited for brain metastases, is presented.

Conclusions:

• Antiangiogenic therapy holds promise for treating brain tumors.
• Further research is needed, particularly for brain metastases.
• Understanding angiogenesis is key to developing effective anti-brain tumor strategies.